KKR’s deal is a bet that financing needs from drug companies will continue to rise. - Michael Nagle/Bloomberg News. KKR has ...

Investment firm KKR (NYSE:KKR) announced on Wednesday the acquisition of a majority stake in biopharma royalty acquisition company, HealthCare Royalty Partners. The acquisition marks KKR's expansion ...

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company ...

Investment giant KKR reported a 9% rise in adjusted net income for the second quarter on Thursday, bolstered by an increase ...

KKR continues its aggressive transformation from traditional private equity into a diversified financial powerhouse through strategic acquisitions and fund initiatives. The investment giant recently ...

Detailed price information for KKR & Company LP (KKR-N) from The Globe and Mail including charting and trades.

Inside KKR's bold $1 trillion playbook: data centers, Harley deals, and the biggest credit fund in its history.

(Reuters) -Investment giant KKR said on Wednesday it had raised $6.5 billion to provide asset-backed financing, as companies ...

The positive earnings surprise came as the alternatives giant revealed new details about its partnership with Capital Group, ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...